ABSTRACT
BACKGROUND

Case Report
A 53 years old woman with no known comorbidities came with chief complaints of drooping of both upper eyelid with double vision since 5 days, unsteadiness while walking since 4 days, nasal intonation and nasal regurgitation for a duration of 2 days.
On admission, patient was afebrile with normal mentation. Her vitals were normal. Neurological Examination revealed -bilateral ptosis; bilaterally dilated pupils not reacting to light; no nystagmus; consensual and accommodation light reflex absent; normal fundus ; absent external ocular movements in all the directions; power -5/5 in all limbs; tone -Hypotonia; deep tendon reflexes and abdominal reflexes absent; plantar bilaterally mute; impaired tandem walking test. All other systemic examinations were normal. History, clinical examination and investigation findings were suggestive of Miller Fisher Syndrome and treatments started with 5 cycle of Plasmapheresis, which were given over a period of 15 days. Patient considerably improved, ptosis slightly decreased and started walking with no unsteadiness after 3 rd cycle of plasmapheresis. Gradual improvement of symptoms was seen day by day and after 3 weeks patient was discharged from the hospital to be followed up in outpatient department.
Investigation
DISCUSSION
Miller Fisher Syndrome (MFS) also called Fisher's syndrome are the clinical triad of ophthalmoplegia, ataxia and areflexia. 4 MFS is named after Dr. C. Miller Fisher who described it in 1956 as a limited variant of ascending paralysis, i.e. GuillainBarré Syndrome (GBS). Though, MFS represents 5 to 10% of GBS cases in Western countries, it is more common in Eastern Asia, accounting for up to 25% of Japanese cases. 5 Miller Fisher syndrome occurs in more men than women by a ratio of approximately 2:1. 6 The mean age of onset of MFS is 43.6 years, though onset has been documented in individuals between the ages of 13 and 78 years. 7 Patients typically seek medical attention because of a rapid decrease in vision over days and/or difficulty walking. These changes are frequently preceded by a viral or diarrheal illness 1 to 4 weeks earlier. Slurred speech, difficulty swallowing and abnormal facial expression with inability to smile or whistle may also occur. Examination shows poor balance and coordination of the hands as well as loss of deep tendon reflexes and eye muscle weakness.
Nerve conduction test may show diminished activity of nerves that carry sensory information to the spinal cord and brain. The most consistent electrophysiological findings in MFS are reduced sensory nerve action potentials and absent H reflexes. More variability is seen with F waves and various investigations involving cranial structures. Magnetic Resonance (MRI) or other imaging of the brain and/or spinal cord are usually normal. Cerebrospinal fluid protein is often elevated (albuminocytologic dissociation). Pure Fisher syndrome is uncommon with many patients going on to develop the prominent widespread weakness of GBS.
Ataxia is primarily noted during the patient's gait, typically in the trunk and with lesser involvement of the limbs. Motor strength is characteristically spared. Anti-GQ1b antibodies, activated by certain strains of Campylobacter jejuni, have a relatively high specificity and sensitivity for MFS. Dense concentrations of GQ1b ganglioside are found in the oculomotor nerve (cranial nerve III), trochlear nerve (cranial nerve IV) and abducens nerve (cranial nerve VI) of patients with MFS, which may explain the relationship between anti-GQ1b antibodies and ophthalmoplegia. 6, 8 Titers of anti-GQ1b antibodies in CSF that are greater than 1:40 are specific for MFS.
The cause(s) of Fisher's syndrome is not completely understood. The waddling, duck-like gait is likely due to the loss of a fat-rich insulating material called myelin around nerves, designated as 1A, that innervate the major sensory organ of muscle called the muscle spindle. As the clinical course progresses, other sensory fibers can be involved as well as motor and autonomic fibers that respectively innervate muscles that move the eyes and face and control function of the eye, pupil and the bladder. Multiple lines of evidence support an autoimmune mechanism in which the preceding/triggering infection stimulates production of an antibody that reacts to a sugar found on both the surface of infectious organism and the peripheral nerve causing demyelination and loss of function of the nerve.
Fortunately, this disorder is often short lived, progressing for only a few weeks and then improving. Anti-GQ1b antibody is one of the key factors in the pathogenesis of MFS, especially for ophthalmoplegia and it is a useful marker in diagnosis of MFS, but it was not done in our case because of unavailability of the test. The combination of absent or reduced sensory responses on clinical electrophysiology testing and elevated protein with a normal white blood cell in CSF could lead to the diagnosis of MFS. 9 MFS symptoms can signal the beginning of GBS with breathing difficulties, which may sometimes lead to respiratory depression, so patients are often hospitalised for observation. In pure MFS, a near full recovery typically occurs within 2 -3 months. In rare cases when symptoms substantially impair function, various treatments that limit or neutralise immune system activity may be considered. These include high dose intravenous immunoglobulin (IVIG) or plasmapheresis (a procedure in which antibodies are removed from the blood) and supportive care. 10 
CONCLUSION
To conclude, a thorough proper history taking, complete physical examination and proper relevant investigations are required to be done so as to diagnose these rare but interesting neurologic disorder which is known as Miller Fisher Syndrome. Though gradual complete recovery is the usual outcome, life-threatening complications can occur if not treated properly at the earliest time. Intravenous immunoglobulin administration or plasmapheresis with conservative management gradually improves the symptoms.
